Sara M. Tolaney, MD, MPH, on Immunotherapy for Breast Cancer: Moving Into Early-Stage Disease

Posted: Tuesday, February 25, 2020

Sara M. Tolaney, MD, MPH, of Dana-Farber Cancer Institute, discusses how immunotherapy has been more successful in other tumor types than breast cancer and whether immune checkpoint inhibition is likely to be most effective in the neoadjuvant setting.